| Description |
ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect[1][2].
|
| Related Catalog |
|
| In Vivo |
ZD-9379 (5 mg/kg) reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion[1]. Animal Model: Male Sprague-Dawley rats weighing 290 to 340 g undergoing permanent middle cerebral artery occlusion (MCAO)[1] Dosage: 5 mg/kg Administration: Group1: a 5-mg/kg bolus of ZD-9379 over 5 minutes followed by 5 mg/kg per hour drug infusion for 4 hours beginning 30 minutes before MCAO.Group 2: (post-MCAO treatment group), a 5-mg/kg bolus of ZD-9379 30 minutes after MCAO followed by 5 mg/kg per hour drug infusion for 4 hours. Result: Initiated before or after MCAO significantly reduced the number of Spreading depressions (SDs) and infarct volume in a permanent focal ischemia model.
|
| References |
[1]. Tatlisumak T, et al. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke. 1998;29(1):190-195. [2]. ZD 9379. Drugs R D. 1999;1(1):44-45.
|
